Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls
← catalyst calendarSponsored by Shionogi (industry) · 4507.T — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
14actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-25 | actual | When the study began enrolling |
| Primary completion | 2025-12-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-15 | actual | The whole study's end, after follow-up |
| First posted | 2025-06-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Renal Impairment
Intervention
- Drug: BPN14770
Primary outcomes
what the primary-completion date above is the date OFMaximum Plasma Concentration (Cmax) of BPN14770
measured 0 (predose) up to 240 hours postdose on Day 1 to Day 11
Time to Reach Cmax (Tmax) of BPN14770
measured 0 (predose) up to 240 hours postdose on Day 1 to Day 11
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration After Dosing (AUC0-last) of BPN14770
measured 0 (predose) up to 240 hours postdose on Day 1 to Day 11
Permalink · 4507.T's whole pipeline · Catalyst calendar · Every registered study · What changed